We are in this
journey together
Dedicated to deliver innovative, disease modifying therapies for patients with mitochondrial dysfunction
From the beginning, working in collaboration with the dedicated advocacy groups, patients and their families, providers and researchers has given us perspective about living with mitochondrial disease and a deep understanding of its course.
The voices of patients are reflected in every step of our journey and inspire our devotion to the cause.
Clinical Trials
Interventional Studies
Primary Mitochondrial Diseases (PMD)
MNV-BM-BLD-001-IL - Phase I/II In Pearson patients (First generation product MNV-101)
Mitochondrial Augmentation Technology (MAT) was evaluated in a clinical trial for Pearson Syndrome: an ultra-rare mitochondrial disease caused by deletions in the mitochondrial genome and characterized by sideroblastic anemia and exocrine pancreas dysfunction. Other clinical features are failure to thrive, pancreatic fibrosis with insulin-dependent diabetes and exocrine pancreatic deficiency, muscle and neurologic impairment, and, frequently, early death. Compassionate use cases of mtDNA deletion syndromes: Seven patients with PS or KSS spectrum disorders have been treated under compassionate use programs in Sheba Medical Center. Details about the results of the compassionate use program have been published in Science Translational Medicine, showing promising safety and efficacy outcomes, Clinical improvements in aerobic function, weight gain and increased strength and endurance were noted.
The findings demonstrate that mitochondrial augmentation therapy is feasible in children with mitochondrial DNA deletion syndromes and that MNV-101 can potentially deliver functional improvement.
This trial ended and not enrolling patients.
MNV-010- Phase I In Pearson patients (Second generation product MNV-201)
Phase I study in Pearson patients started on active and enrolling patients.
Myelodysplastic Syndrome (MDS)
MNV-012 – Phase Ib in MDS Patients (MNV-201; The SHANI Trial)
Phase I study in low risk MDS patients is open and actively enrolling patients.
Born from the tragedy of the October 2023 War, Next October’s mission is to transform grief into progress.
The Next October initiative harnesses Israeli innovation to honor the memory of those lost in the October 2023 War. More than 1,500 innovative startup companies will commemorate the fallen civilians and soldier victims of the war, while building innovative products and services to make for a better world.
Minovia Therapeutics is committed to "doing good" as a core value. We are pledged to honoring the memory of Major Ido Shani, who lost his life on October 7, 2023 at the age of 29. Ido loved the Israeli army and saw his service as a calling. He demonstrated leadership and mentoring qualities and was an exemplary role model to his soldiers, whom he loved. On the morning of October 7, the first day of the war, in the midst of a massive rocket barrage and reports about terrorist infiltration, Ido quickly realized the severity of the situation, mobilized the forces under his control, and approved opening fire. His actions saved many lives.
In his honor, the first in human clinical trial of Minovia’s MNV-201 product in myelodysplastic syndrome (MDS) will be called the SHANI trial. Shani is the color of red in the Hebrew language, the color of the red blood cells these patients lack. May tying this trial to his name bring a hope of red, of Shani, to MDS patients.
Non-Interventional Studies
MNV-007 - MDS samples
Samples collections of MDS patients has started on Q3 2023. The purpose is to study efficacy and mechanism of action of MAT in MDS patient cells.
MNV-008 - PMD samples
Samples collections of PMD patients has started on Q2 2024. The purpose is to establish blood mitochondrial biomarkers for diagnosis of mitochondrial dysfunction.
Sheba Medical Center: graded as one of the top hospitals in the world, is the clinical site for our Phase I/II clinical trial of Mitochondrial Augmentation Technology (MAT) in Pearson syndrome. The study is led by co-Principal Investigators, Professor Amos Toren M.D., Ph.D., MHA, Head of the Division of Pediatric Hemato-oncology, and Elad Jacoby, M.D., Head of the Pediatric Immunotherapy Center. Sheba Medical Center staff have treated 7 patients with MAT on a Compassionate use basis program, through which four children with Pearson syndrome, two patients with Kearns-Sayre syndrome and one patient with Leigh syndrome were treated. Data from the Pearson and KSS patients was used to plan the Phase I/ II trial currently underway, and its results were presented at the annual meeting of the American Society of Hematology (ASH) in San Diego, December 2018, and highlighted during the “Best of Ash” presentation.
Patients resources
Patients’ advocacy organizations are dedicated to support patients, families and caregivers throughout their life journey from diagnosis to living daily with mitochondrial diseases by providing tools and knowledge, creating supportive communities that feels like home to many.
Patients’ advocacy groups are working closely with researchers, regulators and industry to advance development of therapies to patients. Patient registries are one of the tools that have the potential to become a comprehensive database that serves to profoundly educate about the disease and its nature.
In 2020, The Champ Foundation launched the Champ Foundation Registry (CFR) to provide a robust, accessible dataset to families, researchers, clinicians, and companies fighting single large-scale mitochondrial DNA deletion (SLSMD) disorders. To learn more and register, visit: https://cfr.thechampfoundation.org/
